Jeremy Green bought $669K of Fate Therapeutics (FATE)
Executed Dec 20 2024, disclosed Dec 26 2024, 6 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Dec 26 2024), the stock returned -21.2% (delay-adjusted); from the execution session (Dec 20 2024), -20.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Jeremy Green (Director) filed 3 Form 4 reports in the past 24 months (3 purchases, 2 sales, 1 filed past the two-business-day deadline; 2 filings reported both), most often in ADCT. Across 3 priced purchase filings, the average 21-session return was -17.6% from execution and -11.5% from disclosure (delay-adjusted; derived). The largest single filing was $669K of FATE (397,964 sh × $1.68, as filed), executed Dec 20 2024.
Healthcare · Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune dis…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→341,633 sh × $1.68
Exec Dec 20 2024
Filed Dec 26 2024 · 5:30 PM ET †